-
Cancer Res: Scientists hope to redirect antidepressants to treat childhood cancer
Time of Update: 2020-11-29
NOVEMBER 16, 2020 // -- In a recent study published in the international journal Lancer Research, scientists from the Caroline Institute in Sweden and other institutions found that a commonly used antidepressant drug may slow the growth and progression of childhood sarcoma through experiments in mice and laboratory cells, and the results are expected to help develop new targeted therapies for childhood cancer.
-
Prog. Neurobiol: The effects of chronic drinking on the brain's immune system
Time of Update: 2020-11-28
When inflammatory molecules begin to activate and drive neuroimmune responses, anti-inflammatory media provide an important alternative, however, our current understanding of the role of anti-inflammatory signals in key brain regions associated with pathological alcohol dependence behavior is limited, which prevents us from finding a cure for the symptoms in the short term.
-
Nat Neurosci: A link between overactivation of brain astroid cells and the onset of Alzheimer's disease
Time of Update: 2020-11-28
Dr Chun Heejung (IBS), lead author of the study, said: Reactive astrological glial cells are common in a variety of brain diseases, such as Parkinson's disease and brain tumours and Alzheimer's disease.
-
Int. J. Mol. Sci: New study could help relieve Alzheimer's disease
Time of Update: 2020-11-28
(Photo: Www.pixabay.com) In a previous study, the protein design and immunotherapy team at the UAB Department of Biochemistry and Molecular Biology, led by Professor Sandra Villegas, developed an antibody fragment scFv-h3D6 that lowers A-beta levels and improves memory loss in young Alzheimer's model mice.
-
New antipsychotic drugs! ALKS3831 (O nitrogenpin/samidorphan) was rejected by the FDA for treatment of schizophrenia/biphasia type I disorder
Time of Update: 2020-11-28
importantly, no clinical issues related to the efficacy or safety of APKS3831 have been found in the CRL and no new studies are required to support the application for approval.
-
New drugs for children with epilepsy! Vesei Fycompa (Wexter ®, Villenem Panai) has been approved by the European Union to expand the applicable population, has been listed in China!
Time of Update: 2020-11-28
November 18, 2020 // -- Eisai (Eisai) recently announced that the European Commission (EC) has approved the anti-epileptic drug Fycompa (Wycombe ®, common name: perampanel, erampanae) to expand the ap
-
Aging cell: Alzheimer's disease is diagnosed according to the retina
Time of Update: 2020-11-28
the results of the new study, published in the journal Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, came from a clinical trial involving people over the age of 40 who showed signs of cognitive decline.
-
JNNP: Risk Score for Middle-aged and Alzheimer's Disease and Ageing Awareness: A Population-Based Twin Study That Followed For More Than 20 Years
Time of Update: 2020-11-27
conclusion: Middle-aged dementia risk scores predict cognitive function in older adults, but correlations within the twin group rarely support associations independent of common environments and genetic factors.
-
Lancet Neurology: Single gene variation for dystatia: A full sequence study of exons
Time of Update: 2020-11-27
this paper aims to clarify the single gene causes of the main clinical types of dystia.
of all types of dystia, 104 (65%) of the 160 detected variants affected genes associated with neurodevelopmental disorders.
-
Cell: Changes in Tau protein in people with Alzheimer's disease with age
Time of Update: 2020-11-27
Steen lab team studied tau aggregates in two regions of the brain (forehead and angled) in 49 patients with AD and 42 people with Alzheimer's disease or dementia.
-
JNNP: A living PET image of neuro-inflammation in familial frontal dementia
Time of Update: 2020-11-27
authors reported neuroinflamm and abnormal protein aggregation patterns in seven patients with familial frontal lobe dementia (FTD) and used the PK11195 to quantify neuroinfence in patients with symptomatic familial FTD with MAPT, GRN, or C9orf72 mutations.
-
JNNP: Expand the epitype of MOGAD-related diseases: half a century of epilepsy and relapsed optic neuritis
Time of Update: 2020-11-27
esoteric and extensibility of MOGAD." here, the authors describe a new phenomenon in which the authors have followed the synchrotronity of steroid-reactive epilepsy and optic neuritis (ON) recurrence for 48 years in a Mogad sero-positive patient.
-
JNNP: Prevalence, predictor, and prognosis of occasional intracranial aneurysms in patients with suspected transient cerebral ischemic episodes (TIA) and mild stroke: a population-based study and systematic backtracking
Time of Update: 2020-11-27
Unbromed intracranial aneurysms (UIAs) are common occasional imaging manifestations, but little information is available for patients with transient ischemic episodes (TIA)/strokes.
authors identified the prevalence of occasional asymptomatic UIA and the subsequent risk of subcrystrial hemorrhage (SAH) through follow-up to intensive treatment and guideline-based monitoring/management.
-
JAHA: Relationship between partner death and risk of ischemic stroke and cerebral hemorrhage
Time of Update: 2020-11-26
researchers used Cox Proportional Risk Regression to estimate the adjusted risk ratio (aHRs) and corresponding 95% CI over a five-year follow-up period.
-
JNNP: Relationship between lipoprotein E2 genotype and cerebrovascular lesions - 1275 post-brain death studies
Time of Update: 2020-11-26
the purpose of this paper is to study the relationship between lipoprotein E (APOE) genotype and cerebrovascular disease (CVD).
studied 11 lesions of lipoprotein e (APOE) and 1275 cases of cerebrovascular disease (CVD), including obsolescence and recent infarction, haemorrhage, cerebral amyloid vascular disease (CAA) and arteriosclerosis.
-
Lancet Neurol: Patisiran treats genetic thyroxine protein amyloid degeneration for long-term effects and safety studies
Time of Update: 2020-11-26
in a 12-month long-term study, patients with genetic thyroxine protein amyloid degeneration were treated with Patisiran to maintain clinical improvement and good safety.
-
JNNP: Effects of the lute syroid circuit on cognitive flexibility in patients with Huntington's disease: evidence from studies in young patients
Time of Update: 2020-11-26
the purpose of this study was to examine the cognitive flexibility of a far-from-onset Huntington's disease (HD) queue to determine whether there was an early injury and, if so, whether the symposia circuit was associated with the defect.
the CANTAB IED task detected mild impairment of cognitive flexibility in the pre-HD group far from the onset of the disease.
-
Nat Commun: How is the inflammation of the lower pasum brain involved in the diabetes esomore?
Time of Update: 2020-11-25
of the lower pasum brain plays an important role in disrupting eating behavior and energy balance, as well as the pathogenesis of obesity and diabetes.
-
JNNP: Serum nerve wire light chain predicts long-term prognosis in patients with Green-Bally syndrome
Time of Update: 2020-11-25
single-molecule array (SiMoA) was used to measure NfL in the serum (98 cases) and cerebrospinal fluid (CSF) of GBS patients in the Spanish International GBS Results Study (IGOS) and compared it with 53 health control groups (HCs).
-
JNNP: Systematic evaluation of psychotherapy for functional neurological disorders in adults
Time of Update: 2020-11-25
While the lack of high-quality PDT controlled trials is a significant limitation, the results of the two treatment types are largely comparative, and the lack of long-term follow-up data in most identified CBT trials is also an important limitation.
